Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.53 |
| ▸ | CTSV | O60911 | 4/20 | 0.53 |
| ▸ | CTSL | P07711 | 3/20 | 0.53 |
| ▸ | CTSK | P43235 | 4/20 | 0.49 |
| ▸ | CCR1 | P32246 | 4/20 | 0.41 |
| ▸ | CCKBR | P32239 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6797542 | 0.95 | CTSS (0.49) | CTSSCTSVCTSLCTSKCCR1 | |
| SCHEMBL6803456 | 0.91 | CTSS (0.51) | CTSSCTSVCTSLCTSKCCR1 | |
| SCHEMBL4450417 | 0.89 | CTSS (0.67) | CTSSCTSVCTSLCTSKCCR1 | |
| SCHEMBL6796912 | 0.87 | CTSS (0.60) | CTSSCTSVCTSLCTSKCCR1 | |
| SCHEMBL13677211 | 0.87 | CTSS (0.60) | CTSSCTSVCTSLCTSKCCR1 | |
| SCHEMBL4449168 | 0.87 | CTSS (0.60) | CTSSCTSVCTSLCTSKCCR1 | |
| SCHEMBL6802733 | 0.86 | CTSS (0.48) | CTSSCTSVCTSLCTSKCCR1 | |
| SCHEMBL6807727 | 0.85 | CTSK (0.64) | CTSSCTSVCTSLCTSKCCR1 | |
| SCHEMBL4451492 | 0.85 | CTSK (0.64) | CTSSCTSVCTSLCTSKCCR1 | |
| SCHEMBL7154653 | 0.85 | CTSK (0.64) | CTSSCTSVCTSLCTSKCCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | GRUNENTHAL GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | CTSS 39/4885CTSV 27/4885CTSL 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.